Lund, Sweden – March 21, 2019 – BioInvent International AB (OMXS: BINV) announced today that the Company will host three investor events in connection with the ongoing capitalization of the Company. At the events, Martin Welschof, CEO of BioInvent, will give the current corporate presentation and he and other members of the BioInvent management team will be available for a question and answer session.    

Stockholm
Date: Thursday, March 28, 2019
Time: 18.00 – 20.00 CET
Location: Scandic Anglais, Humlegårdsgatan 23, 102 44, Stockholm

Malmö
Date: Tuesday, April 9, 2019
Time: 18.00 – 20.00 CET
Location: Elite Hotel Savoy, Norra Vallgatan 62, 201 80, Malmö

Gothenburg
Date: Wednesday, April 10, 2019
Time: 18.00 – 20.00 CET
Location: Clarion Hotel Post, Drottningtorget 10, 411 03, Gothenburg

To register to attend the events, please send an email to [email protected] with your full name and the selected location (Stockholm, Malmö or Gothenburg).

 
About BioInvent
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company’s lead program is BI-1206, currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent’s pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.

For further information, please contact:

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com